Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 807

PRETRIAL MEMORANDUM by F. Hoffmann-LaRoche LTD, Amgen Inc.. (Attachments: #1 Exhibit A (Amgen's Contested Issues of Fact)#2 Exhibit B (Roche's Statement of Contested Issues of Fact)#3 Exhibit C (Amgen's Legal Standards and Burden of Proof)#4 Exhibit D (Roche's Statement of Legal Standards and Burdens of Proof)#5 Exhibit E (Amgen's List of Witnsses for Trial)#6 Exhibit F (Roche's List of Potential Witnesses))(Gottfried, Michael)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 807 Att. 3

Case 1:05-cv-12237-WGY

Document 807-4

Filed 08/10/2007

Page 1 of 2

Exhibit C Amgen's Legal Standards and Burden of Proof
VI. ISSUES OF LAW, INCLUDING EVIDENTIARY QUESTIONS, TOGETHER WITH SUPPORTING AUTHORITY A. Amgen's Position 1. Legal Standards and Burden of Proof1

Infringement. Amgen must prove, by a preponderance of the evidence, that Roche's manufacture, use, sale, offer to sell, or importation of glycosylated recombinant human erythropoietin, glycosylated recombinant human erythropoietin-containing products, "RO0503821," "Ro 050-3821,""R744," "Continuous Erythropoiesis Receptor Activator," "CERA," "pegserepoetin alfa," "methoxy polyethylene glycol-epoetin beta," or "MIRCERAŽ" (hereinafter referred to as "peg-EPO") will satisfy every limitation of the claims-in-suit either literally or under the Doctrine of Equivalents. See 35 U.S.C. § 271; Cross Med. Prods. v. Medtronic Sofamor Danek, Inc., 424 F.3d 1293, 1310 (Fed. Cir. 2005). Invalidity. The patents-in-suit are presumed valid. See 35 U.S.C. § 282. Roche must prove, by clear and convincing evidence, that the patents-in-suit are invalid. See Robotic Vision Sys. V. View Eng'g, Inc., 189 F.3d 1370, 1377 (Fed. Cir. 1999). Section 282 states: "Each claim of a patent (whether in independent, dependent, or multiple dependent form) shall be presumed valid independently of the validity of other claims . . ." Therefore, the invalidity of each claim must be proved independently, and "a party challenging the validity of a claim . . . must submit evidence supporting a conclusion of invalidity of each claim the challenger seeks to destroy."

1

Amgen disagrees with numerous mischaracterizations of the law in Roche's Issues of Law statement. Amgen intends to file bench memos identifying and correcting these mischaracterizations.

755096

-1-

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 807-4

Filed 08/10/2007

Page 2 of 2

Shelcore, Inc. v. Durham Indus., Inc., 745 F.2d 621, 625 (Fed. Cir. 1984); see also Dayco Prods., Inc. v. Total Containment, Inc., 329 F.2d 1358, 1370-1371 (Fed. Cir. 2003). Unenforceability. To establish that the patents-in-suit are unenforceable based on inequitable conduct, Roche must prove, by clear and convincing evidence, the misrepresentation or withholding of a material fact from the Patent Office with an intent to deceive. See FMC Corp. v. Manitowoc Co., 835 F.2d 1411, 1415 (Fed. Cir. 1987); Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867, 872 (Fed. Cir. 1988).

755096

-2-